Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company developing innovative vaccines, is advancing TNX-801, a live, minimally replicatin ...

Vaccinia virus (VACV) confers cross-protective immunity against the variola virus, the causative agent of smallpox, and has therefore been extensively exploited as a preventive vaccine.

The immune system can typically ramp up the body's defenses to clear out an invading threat without issue. Glitches can ...

Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.

One dose of the Jynneos vaccine was 58% effective against mpox infection overall and 84% in people without HIV, but only 35% ...

One of the molecular fragments (pink) uncovered using fragment-based drug discovery is shown binding with an immune system enzyme called Vaccinia-H1-related phosphatase.

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% ...

This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of ...